Update on therapeutic approaches for invasive fungal infections in adults.

IF 3.8 Q2 INFECTIOUS DISEASES
Therapeutic Advances in Infectious Disease Pub Date : 2024-01-20 eCollection Date: 2024-01-01 DOI:10.1177/20499361231224980
Catherine-Audrey Boutin, Me-Linh Luong
{"title":"Update on therapeutic approaches for invasive fungal infections in adults.","authors":"Catherine-Audrey Boutin, Me-Linh Luong","doi":"10.1177/20499361231224980","DOIUrl":null,"url":null,"abstract":"<p><p>Invasive fungal infections are increasingly encountered with the expansion of iatrogenic immunosuppression, including not only solid organ and hematopoietic stem cell transplant recipients but also patients with malignancies or autoimmune diseases receiving immunomodulatory therapies, such as Bruton Tyrosine Kinase (BTK) inhibitor. Their attributable mortality remains elevated, part of which is a contribution from globally emerging resistance in both molds and yeasts. Because antifungal susceptibility test results are often unavailable or delayed, empiric and tailored antifungal approaches including choice of agent(s) and use of combination therapy are heterogeneous and often based on clinician experience with knowledge of host's net state of immunosuppression, prior antifungal exposure, antifungal side effects and interaction profile, clinical severity of disease including site(s) of infection and local resistance data. In this review, we aim to summarize previous recommendations and most recent literature on treatment of invasive mold and yeast infections in adults to guide optimal evidence-based therapeutic approaches. We review the recent data that support use of available antifungal agents, including the different triazoles that have now been studied in comparison to previously preferred agents. We discuss management of complex infections with specific emerging fungi such as <i>Scedosporium</i> spp., <i>Fusarium</i> spp., <i>Trichosporon asahii</i>, and <i>Candida auris</i>. We briefly explore newer antifungal agents or formulations that are now being investigated to overcome therapeutic pitfalls, including but not limited to olorofim, rezafungin, fosmanogepix, and encochleated Amphotericin B. We discuss the role of surgical resection or debridement, duration of treatment, follow-up modalities, and need for secondary prophylaxis, all of which remain challenging, especially in patients chronically immunocompromised or awaiting more immunosuppressive therapies.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"11 ","pages":"20499361231224980"},"PeriodicalIF":3.8000,"publicationDate":"2024-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10799587/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Infectious Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20499361231224980","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Invasive fungal infections are increasingly encountered with the expansion of iatrogenic immunosuppression, including not only solid organ and hematopoietic stem cell transplant recipients but also patients with malignancies or autoimmune diseases receiving immunomodulatory therapies, such as Bruton Tyrosine Kinase (BTK) inhibitor. Their attributable mortality remains elevated, part of which is a contribution from globally emerging resistance in both molds and yeasts. Because antifungal susceptibility test results are often unavailable or delayed, empiric and tailored antifungal approaches including choice of agent(s) and use of combination therapy are heterogeneous and often based on clinician experience with knowledge of host's net state of immunosuppression, prior antifungal exposure, antifungal side effects and interaction profile, clinical severity of disease including site(s) of infection and local resistance data. In this review, we aim to summarize previous recommendations and most recent literature on treatment of invasive mold and yeast infections in adults to guide optimal evidence-based therapeutic approaches. We review the recent data that support use of available antifungal agents, including the different triazoles that have now been studied in comparison to previously preferred agents. We discuss management of complex infections with specific emerging fungi such as Scedosporium spp., Fusarium spp., Trichosporon asahii, and Candida auris. We briefly explore newer antifungal agents or formulations that are now being investigated to overcome therapeutic pitfalls, including but not limited to olorofim, rezafungin, fosmanogepix, and encochleated Amphotericin B. We discuss the role of surgical resection or debridement, duration of treatment, follow-up modalities, and need for secondary prophylaxis, all of which remain challenging, especially in patients chronically immunocompromised or awaiting more immunosuppressive therapies.

成人侵袭性真菌感染治疗方法的最新进展。
随着先天性免疫抑制的扩大,侵袭性真菌感染越来越多,不仅包括实体器官和造血干细胞移植受者,还包括接受布鲁顿酪氨酸激酶(BTK)抑制剂等免疫调节疗法的恶性肿瘤或自身免疫性疾病患者。他们的可归因死亡率仍然很高,其中一部分原因是全球范围内新出现的霉菌和酵母菌的抗药性。由于抗真菌药敏试验结果往往无法获得或延迟获得,因此经验性和有针对性的抗真菌方法(包括药物选择和联合疗法的使用)是多种多样的,而且往往基于临床医生的经验,包括对宿主免疫抑制净状态的了解、之前抗真菌药物的接触、抗真菌药物的副作用和相互作用概况、疾病的临床严重程度(包括感染部位)以及当地的耐药性数据。在本综述中,我们旨在总结以往关于成人侵袭性霉菌和酵母菌感染治疗的建议和最新文献,以指导最佳循证治疗方法。我们回顾了支持使用现有抗真菌药物的最新数据,包括与以前首选药物相比,现在研究的不同三唑类药物。我们还讨论了对新出现的特殊真菌(如 Scedosporium spp.、Fusarium spp.、Trichosporon asahii 和 Candida auris)复杂感染的治疗。我们简要探讨了目前正在研究以克服治疗误区的新型抗真菌药物或制剂,包括但不限于奥罗芬、雷沙芬净、福斯马诺吉匹克和环孢素 B。我们讨论了手术切除或清创的作用、治疗持续时间、随访方式和二次预防的必要性,所有这些仍然具有挑战性,尤其是对于长期免疫力低下或等待更多免疫抑制疗法的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.30
自引率
8.80%
发文量
64
审稿时长
9 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信